Kala Bio (KALA) Non-Current Assets (2016 - 2025)
Kala Bio (KALA) posted Non-Current Assets of $747000.0 for Q3 2025, down 68.74% sequentially from $2.4 million in Q2 2025, and down 73.32% YoY from $2.8 million in Q3 2024.
Kala Bio (KALA) Non-Current Assets (2016 - 2025) Analysis & Trends
Kala Bio has reported Non-Current Assets for 10 years, with the latest figure at $747000.0 in Q3 2025.
- Quarterly Non-Current Assets fell 73.32% year-over-year to $747000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 70.88% YoY) and the FY2024 annual result came in at $2.7 million, down 12.76% from the prior year.
- Non-Current Assets fell to $747000.0 in Q3 2025 per KALA's latest filing, from $2.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $50.8 million in Q1 2021 and troughed at $747000.0 in Q3 2025.
- A 5-year average of $10.3 million and a median of $2.8 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slumped 97.71% in 2022, then soared 250.68% in 2023.
- Over 5 years, Non-Current Assets stood at $15.1 million in 2021, then tumbled by 94.17% to $878000.0 in 2022, then jumped by 250.68% to $3.1 million in 2023, then fell by 12.76% to $2.7 million in 2024, then sank by 72.19% to $747000.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $747000.0, $2.4 million, and $2.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 747,000.00 |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.54 Mn |
| Dec 31, 2024 | 2.69 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.75 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 3.08 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 965,000.00 |
| Mar 31, 2023 | 882,000.00 |
| Dec 31, 2022 | 878,000.00 |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 13.32 Mn |
| Dec 31, 2021 | 15.06 Mn |
| Sep 30, 2021 | 44.73 Mn |
| Jun 30, 2021 | 43.74 Mn |
| Mar 31, 2021 | 50.76 Mn |
| Dec 31, 2020 | 50.23 Mn |